GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » PetVivo Holdings Inc (OTCPK:PETV) » Definitions » YoY EBITDA Growth

PETV (PetVivo Holdings) YoY EBITDA Growth : 31.67% (As of Dec. 2024)


View and export this data going back to 2012. Start your Free Trial

What is PetVivo Holdings YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. PetVivo Holdings's YoY EBITDA Growth for the quarter that ended in Dec. 2024 was 31.67%.

PetVivo Holdings's EBITDA per Share for the three months ended in Dec. 2024 was $-0.08.

PetVivo Holdings YoY EBITDA Growth Historical Data

The historical data trend for PetVivo Holdings's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PetVivo Holdings YoY EBITDA Growth Chart

PetVivo Holdings Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 67.81 -7.47 -88.74 -47.89 10.91

PetVivo Holdings Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.90 36.92 56.10 52.68 31.67

PetVivo Holdings YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

PetVivo Holdings's YoY EBITDA Growth for the fiscal year that ended in Mar. 2024 is calculated as:

YoY EBITDA Growth (A: Mar. 2024 )
=(EBITDA per Share (A: Mar. 2024 )-EBITDA per Share (A: Mar. 2023 ))/ | EBITDA per Share (A: Mar. 2023 ) |
=(-0.751--0.843)/ | -0.843 |
=10.91 %

PetVivo Holdings's YoY EBITDA Growth for the quarter that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (Q: Dec. 2024 )
=(EBITDA per Share (Q: Dec. 2024 )-EBITDA per Share (Q: Dec. 2023 )) / | EBITDA per Share (Q: Dec. 2023 )) |
=(-0.082--0.12)/ | -0.12 |
=31.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PetVivo Holdings YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of PetVivo Holdings's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

PetVivo Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » PetVivo Holdings Inc (OTCPK:PETV) » Definitions » YoY EBITDA Growth
Comparable Companies
PAVM TRIB CODX BTCY ALUR AXDX SSKN RMSL LUDG VVOS ABT BSX SYK MDT XTER:SHL EW SZSE:300760 DXCM XAMS:PHIA STE
Traded in Other Exchanges
N/A
Address
5151 Edina Industrial Boulevard, Suite 575, Edina, MN, USA, 55439
Website
https://www.petvivo.com
PetVivo Holdings Inc is an emerging biomedical device company. It is focused on the manufacturing, commercialization, and licensing of medical devices and therapeutics for companion animals. The product pipeline includes approximately seventeen products intended to treat animals and people. Its patent protection extends to biomaterials, products, production processes, and methods of use provided by the company's portfolio of several patents. The company has also begun the commercialization of its product Spryng with OsteoCushion technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions such as osteoarthritis in dogs and horses.
Executives
John Lai director, 10 percent owner, officer: CEO 12100 SINGLETREE LANE, SUITE 186, EDEN PRAIRIE MN 55344
James Rudolph Martin director POBOX 53988, IRVINE CA 92619
A.l. Sarroff Fund, Llc 10 percent owner 43 MEADOW WOODS ROAD, GREAT NECK NY 11020
John Spencer Breithaupt director 3041 W. PASADENA DR., BOISE ID 83705
Robert J Costantino director 5805 SEPULVEDA BLVD., SUITE 801, SHERMAN OAKS CA 91411
Joseph William Jasper director 201 SOUTH 11TH STREET, UNIT 1030, MINNEAPOLIS MN 55403
Robert James Rudelius director 6913 ARBOR LANE, MCCLEAN VA 22101
Leslie Anne Coolidge director 345 OLD SUTTON ROAD, BARRINGTON HILLS IL 60010
Robert J. Folkes officer: Chief Financial Officer 1331 TYLER STREET NE, SUITE 200, MINNEAPOLIS MN 55413
Scott Mitchell Johnson director 475 LAKESHORE UNIT #32, INCLINE VILLAGE NV 89451
James Joseph Martin director 4400 BISCAYNE BLVD, SUITE # 670, MIAMI FL 33157
Gregory D Cash director
John Michael Carruth officer: Acting Chief Financial Officer 4923 RIVER WOOD DR., SAVAGE MN 55439
Sherry Grisewood director 377 FAIRMOUNT ROAD, CALIFON NJ 07830
David Don Deming director 16200 45TH STREET SOUTH, AFTON MN 55001